Literally just mainlining marketing material straight into whatever’s left of their rotting brains.

  • Sphere [he/him, they/them]@hexbear.net
    link
    fedilink
    English
    arrow-up
    2
    ·
    edit-2
    1 year ago

    So, after taking some time to digest this information, I have a couple of follow-up questions, if you don’t mind answering them.

    First of all, where do things stand with drugs? Is it just not something academics are working on, but presumably being done (or already finished) within proprietary institutions (e.g. Big Pharma)? Can you point me to some recent papers on the subject?

    Secondly, what about enzymes? Binding proteins are interesting, certainly, but it’s enzymes that really excite me the most. Is anyone working on custom enzyme design, and if so, can you link some papers on that? In looking more closely at that Nature paper, I see that enzymes are something of a work-in-progress as yet. If you have anything else on the subject, I’d welcome that, but if there’s nothing else of note there, that’s fine.

    Thank you for mentioning this to begin with, by the way, I really appreciate the info you’ve already shared!

    • plinky [he/him]@hexbear.net
      link
      fedilink
      English
      arrow-up
      2
      ·
      edit-2
      1 year ago

      With drugs third paper references it, i think in the next 6 months people expect neural net check of compounds binding affinities (https://www.biorxiv.org/content/10.1101/2023.11.01.565201v1.abstract), but here quantum chemistry is lagging behind, they still can’t do large molecules (>30 atoms) reliably. Basically rn the big bad boy is david baker lab, they do all this exciting stuff, you can periodically check google scholar for new developments like i do.

      With enzymes (as i understand) the problem is to make them work, they can make them bind, but they can’t make them move to do stuff.

      Alphafold can’t make conformations for now, and its a harder problem, so maybe in 2 years they can develop something reliable, as for now its mainly shenanigans of biasing folding programs into new conformations